Navigation Links
Ampio Pharmaceuticals Announces a Proof of Concept Trial of Danazol in the Treatment of Allergic Rhinitis Supports Mechanism of Action of Optina™
Date:10/18/2011

GREENWOOD VILLAGE, Colo., Oct. 18, 2011 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NASDAQ: AMPE) ("Ampio" or the "Company"), a company that discovers and develops new uses for previously approved drugs and new molecular entities ("NMEs"), today announced that it has demonstrated in an IRB approved, randomized, placebo controlled, double-blinded proof of concept study, that low dose intranasal danazol has an impact on allergic rhinitis, a clinical condition in which increases in vascular permeability and edema are hallmark signs.

The study was not powered to show statistical significance as an effective treatment for rhinitis but rather intended to investigate the effect of danazol in a clinical condition associated with vascular permeability and edema.  After a 7 day washout period, patients were treated twice a day for 14 days with either placebo (n=10) or low-dose intranasal danazol (n=10) and assessed two times per day (AM and PM) using the validated Total Nasal Symptom Score (TNSS).  A larger decrease in TNSS indicates a greater improvement in symptoms.  A comparison of the PM score showed a strong trend toward efficacy, with a total mean change between washout and treatment of -2.39 for the treatment group compared to -0.34 for the placebo (p=0.10).  

"The pathogenesis of edema is very similar in different diseases.  The fact that low dose danazol could decrease edema in this setting is exciting, as it may indicate a similar impact of Optina™ on DME (Diabetic Macular Edema)," said Dr. Vaughan Clift, Chief Regulatory Officer of Ampio Pharmaceuticals, noting that "an oral formulation of low dose danazol (Optina™) is already the subject of a placebo-controlled, dose ranging trial in DME, the results of which are expected in Q2 2012."

About Optina(TM) (danazol)

Danazol is a weak androgen approved at high do
'/>"/>

SOURCE Ampio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Ampio Pharmaceuticals Receives Notice of Allowance of its Two Patent Applications on the Combination of Zertane™ with Erectile Dysfunction Drugs in Canada
2. Ampio Announces Positive Results From 12-Week Open Label Extension Study of Zertane™ in Patients With Premature Ejaculation.
3. Champions Oncology Reports Fiscal 2012 First Quarter Financial Results
4. Ampio Pharmaceuticals Executes License and Development Agreement with Daewoong Co. Ltd. to Commercialize Zertane™ in South Korea
5. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
6. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
7. Ampio Pharmaceuticals Set to Join Russell 3000 Index
8. Ampio Pharmaceuticals, Inc. Appoints New Independent Director
9. Ampio Pharmaceuticals, Inc. to Begin Trading on the NASDAQ Capital Market
10. Ampio Pharmaceuticals, Inc. Receives Approval to List on the NASDAQ Capital Market
11. Five Californians Selected as Breakaway from Cancer® Champions to be Honored During Amgen Tour of California
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... and Market Analysis to 2022 ... Dermatitis - India Drug Forecast and Market ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... BURLINGTON, Mass., Dec. 12, 2011 /PRNewswire-iReach/ -- ... Financial. Tom joined Ametros as executive vice president in ... in the workers, compensation managed care industry. He served ... Medical, vice president of national occupational health for Kaiser ...
... Ontario, Dec. 12, 2011  Valeant Pharmaceuticals International, Inc. ... at a special meeting of shareholders of Afexa ... today in Calgary, Alberta, the shareholders of Afexa ... subsidiary, 1625907 Alberta Ltd. (the " Offeror ") ...
Cached Medicine Technology:Ametros Financial Names Thomas Ash as CEO 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 2Valeant Announces the Completion of the Privatization of Afexa Life Sciences Inc. 3
(Date:4/18/2014)... have been awarded two-year grants for their work on ... Of the 110 initial submissions to the new Novo ... four projects were funded, three of which are led ... Ph.D.; G. William Wong, Ph.D.; and Elias Zambidis, M.D., ... will use his $500,000 proof of principle grant to ...
(Date:4/18/2014)... available in French . ... practice and regenerative medicine. A team led by Ludwik ... Paris Tech) and Didier Letourneur from the Laboratoire Recherche ... just demonstrated that the principle of adhesion by aqueous ... repair soft-tissue organs and tissues. This easy-to-use gluing method ...
(Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... 2014) Doctors who treat patients with a ... can face an agonizing treatment decision. , The ... and help relieve shortness of breath. But some ... can cause potentially fatal complications following transplantation. , ... Dilling, medical director of Loyola University Medical Center,s ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... the arm by way of a novel research conducted by ... endowed with the potential to inhibit the growth of blood ... may throw open a plethora of options to fight cancer ... University, previous research has indicated the benefits of aspirin in ...
... down for decades, ever since studies showed a strong link ... experts have suggested that some people should aim even lower, ... called low-density lipoprotein for some high-risk people — even if ... there. ,Not so fast, says a team of researchers ...
... Among patients with schizophrenia whose medication is changed ... antipsychotic drugs do not appear to offer significant ... a report in the October issue of Archives ... ,The findings run contrary to the ...
... less than 2,000 grams (about 4.5 pounds) at birth ... the average teenager to have physical and mental difficulties, ... Archives of Pediatrics & Adolescent Medicine, one of the ... increase the risk for major disabilities such as cerebral ...
... unexplored regions of the human genome are thousands of ... growth of breast cancer is driven by estrogen, new ... ,In the October issue of Nature Genetics, the investigators ... panels" -- stretches of DNA that turn genes on ...
... has apologized to a woman who had a miscarriage in ... to go through the process.// ,On Tuesday Health region ... are sorry that this situation occurred and we empathize with ... the circumstances of this case, as we do with all ...
Cached Medicine News:Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 2Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 3Health News:No Clear Evidence for Ultra-Low Cholesterol Targets? 4Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 2Health News:New Antipsychotic Medications have Little Advantage Over Older Drugs 3Health News:Low Birth Weight Babies May Have Mental & Physical Problems 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 2Health News:New Tool for Understanding Estrogen-Fueled Breast Cancer 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: